colistimethate

colistimethate

 [ko-lis″tĭ-meth´āt]
an antibiotic that is a colistin derivative; the sodium salt is used in treatment of infections.

colistimethate

/col·is·ti·meth·ate/ (ko-lis″tĭ-meth´āt) a colistin derivative; the sodium salt is used as an antibacterial.

colistimethate

an antibiotic prepared from colistin.
References in periodicals archive ?
Synereca's lead program will combine a potentiator with Colistin (polymyxin E, colistimethate sodium) for the treatment of serious hospital-associated infections caused by resistant Gram-Negative bacteria, a $2.
The form available in South Africa is a prodrug, colistimethate sodium or colistin methanesulfonate (CMS), which makes a bolus dose necessary to achieve therapeutic effect.
Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis.
APP's version, called Colistimethate, will be shipped immediately, the company said.
To the Editor: Sodium colistimethate (colistin) is a parenterally administered polymyxin antibiotic that acts by disrupting bacterial cell membranes.
Like colistimethate, amphotericin is associated with severe systemic adverse effects, including nephrotoxicity and hepatotoxicity.
NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P.
An additional problem is that prescribing units differ between manufacturers, including mg for colistin base activity (CBA) and colistimethate sodium (CMS), and international units for CMS.
were susceptible only to colistimethate sodium whereas S.
LONDON, September 15 /PRNewswire/ -- Forest Laboratories UK Ltd, (a wholly owned subsidiary of Forest Laboratories Inc) announced that following the successful completion of its pan-European multi-centre phase III study (the Freedom Study), it has applied to the European Medicines Evaluation Agency (EMEA) to licence its new formulation dry powder colistimethate sodium for inhalation (Colobreathe(R)) for use by Cystic Fibrosis patients.